NEW YORK (GenomeWeb News) - Agendia has begun the US roll-out of its MammaPrint breast cancer test, which is aimed at helping physicians predict the likelihood of cancer metastasis, through agreements with two university reference centers.
 
Agendia COO Jan Groen said in a statement that the first US centers offering the test are the University of California at San Francisco’s Medical Center at Mount Zion and the Baylor College of Medicine’s Dan L. Duncan Cancer Center.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.